selected publications
- Discovery of a first-in-class SLIT2 binder disrupting the SLIT2/ROBO1 axis via DNA-encoded library (DEL) screening. RSC medicinal chemistry. 2025 Academic Article GET IT
- Discovery and validation of LAGi-DEL: A nanomolar LAG-3 inhibitor that reverses immune suppression in tumor-immune co-culture models. European journal of medicinal chemistry. 2025 Academic Article GET IT
- Discovery and Optimization of LAG-3-Targeted Small Molecules via DNA-Encoded Chemical Library (DEL) Screening for Cancer Immunotherapy. Journal of medicinal chemistry. 2025 Academic Article GET IT
-
Temperature-related intensity change (TRIC)-based high-throughput screening enables the discovery of small molecule CD28 binders.
SLAS discovery : advancing life sciences R & D.
2025
Academic Article
GET IT
Times cited: 2 - HTS-Oracle: A Retrainable AI Platform for High-Confidence Hit Identification Across Difficult-to-Drug Targets. 2025 GET IT
- Discovery of a First-in-Class SLIT2 Binder Disrupting the SLIT2/ROBO1 Axis via DNA-Encoded Library (DEL) Screening. 2025 GET IT
- Surface Plasmon Resonance (SPR)-Based Workflow for High-Throughput Discovery of CD28-Targeted Small Molecules. 2025 GET IT
- TRIC-Based High-Throughput Screening Enables the Discovery of Small Molecule CD28 Binders. 2025 GET IT
- TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional Characterization. 2025 GET IT
-
Computational Design of a Bicyclic Peptide Inhibitor Targeting the ICOS/ICOS-L Protein-Protein Interaction.
Chemical biology & drug design.
2025
Academic Article
GET IT
Times cited: 2 -
Discovery of ICOS-Targeted Small Molecules Using Affinity Selection Mass Spectrometry Screening.
ChemMedChem.
2024
Academic Article
GET IT
Times cited: 7 -
From Virtual Screens to Cellular Target Engagement: New Small Molecule Ligands for the Immune Checkpoint LAG-3.
ACS medicinal chemistry letters.
2024
Academic Article
GET IT
Times cited: 4 -
Design and Biophysical Characterization of Second-Generation cyclic peptide LAG-3 inhibitors for cancer immunotherapy.
Bioorganic & medicinal chemistry letters.
2024
Academic Article
GET IT
Times cited: 1 - Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening. 2024 GET IT
-
Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction.
Bioorganic & medicinal chemistry letters.
2024
Academic Article
GET IT
Times cited: 8 -
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches.
Journal of personalized medicine.
2024
Review
GET IT
Times cited: 14 -
Discovery of ICOS-Targeted Small Molecules Using Pharmacophore-Based Screening.
ChemMedChem.
2023
Academic Article
GET IT
Times cited: 10 -
Molecular signature associated with cladribine treatment in patients with multiple sclerosis.
Frontiers in immunology.
2023
Academic Article
GET IT
Times cited: 4 -
Gut Microbial-Derived Metabolites as Immune Modulators of T Helper 17 and Regulatory T Cells.
International journal of molecular sciences.
2023
Review
GET IT
Times cited: 28 -
Therapeutic Effect of IL-21 Blockage by Gene Therapy in Experimental Autoimmune Encephalomyelitis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2022
Academic Article
GET IT
Times cited: 7 -
Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage.
Clinical and translational medicine.
2022
Letter
GET IT
Times cited: 123 -
Immunomodulatory Effects Associated with Cladribine Treatment.
Cells.
2021
Academic Article
GET IT
Times cited: 20 -
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
Multiple sclerosis (Houndmills, Basingstoke, England).
2021
Academic Article
GET IT
Times cited: 1 -
Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2021
Academic Article
GET IT
Times cited: 31 -
How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process.
Gut microbes.
2020
Academic Article
GET IT
Times cited: 35 -
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2020
Academic Article
GET IT
Times cited: 9 -
NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients.
Brain : a journal of neurology.
2020
Academic Article
GET IT
Times cited: 108 -
Chitinase 3-like 1 is neurotoxic in primary cultured neurons.
Scientific reports.
2020
Academic Article
GET IT
Times cited: 30 -
A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis.
Cells.
2020
Academic Article
GET IT
Times cited: 41 -
Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
The American journal of pathology.
2018
Academic Article
GET IT
Times cited: 24 -
Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis.
Autoimmunity reviews.
2017
Review
GET IT
Times cited: 78 -
Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation.
Brain, behavior, and immunity.
2017
Review
GET IT
Times cited: 24 -
Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.
Molecular neurobiology.
2016
Academic Article
GET IT
Times cited: 27 -
Metabolic responses of CHO cells to limitation of key amino acids.
Biotechnology and bioengineering.
2014
Academic Article
GET IT
Times cited: 80 -
Metabolic signatures of GS-CHO cell clones associated with butyrate treatment and culture phase transition.
Biotechnology and bioengineering.
2013
Academic Article
GET IT
Times cited: 87